Learn about iGBS
WHAT IS iGBS?
Invasive Group B Streptococcus (iGBS) is a serious bacterial infection that can occur in newborns and infants, often leading to severe complications such as sepsis, pneumonia, or meningitis. It poses significant health risks, including potential long-term effects like Neurodevelopmental Impairment (NDI).
​
WHEN CAN A CHILD BE AFFECTED BY iGBS INFECTION?
A child can be affected by invasive Group B Streptococcus (iGBS) at various points, typically categorized into three timeframes based on when the infection occurs.
WHEN CAN A CHILD BE AFFECTED BY iGBS INFECTION?
A child can be affected by invasive Group B Streptococcus (iGBS) at various points, typically categorized into three timeframes based on when the infection occurs.
01.
DURING PREGNANCY
Although rare, a fetus can be affected by GBS while still in the womb. This can happen if the bacteria ascend from the mother's genital tract into the uterus.
Possible effects include:
-
Premature rupture of membranes (PROM)
-
Preterm birth or miscarriage
-
Stillbirth caused by severe infection in the fetus
03.
AFTER BIRTH (Late-Onset iGBS)
Late-onset iGBS occurs when the infection develops after the baby is born. The source of infection can vary, including:
Contact with the mother’s GBS bacteria post-delivery.
Exposure to caregivers or contaminated environments.
Timeframe
Late-onset iGBS generally occurs between 7 days and 3 months of age but can happen later in some cases.
Common symptoms include:
-
Lethargy or irritability
-
Poor feeding
-
Fever
-
Meningitis (more common in late-onset iGBS)
Prevention Challenges
Unlike early-onset iGBS, late-onset infections are not effectively prevented by Intrapartum Antibiotic Prophylaxis (IAP) during delivery.
02.
AT BIRTH (Early-Onset iGBS)
This occurs when a baby is exposed to GBS during delivery. If the mother is colonized with GBS in her genital tract, the bacteria can be transmitted to the baby during vaginal delivery.
​
Timeframe
Early-onset iGBS typically occurs within the first 7 days of life, with most cases presenting within the first 24 hours after birth.
Common symptoms include:
-
Respiratory distress (difficulty breathing).
-
Fever or hypothermia.
-
Lethargy, poor feeding.
-
Sepsis, pneumonia, or meningitis.
​
Prevention
Administering intrapartum antibiotic prophylaxis (IAP) to mothers who test positive for GBS colonization can significantly reduce the risk.
Why focus on iGBS?
While advancements in medicine have improved outcomes for many affected infants, iGBS can still result in long-term neurodevelopmental impairments (NDI) that affect a child’s quality of life and require lifelong care. By focusing on iGBS, we aim to enhance early detection, provide comprehensive support to families, and advance research into better prevention, treatment, and care strategies. Addressing iGBS is essential to reducing its impact on families and improving health outcomes for children globally.
Why focus on neurological development?
Healthy neurological development is essential for a child’s ability to learn, communicate, and build motor and social skills. When neurological development is disrupted, it can affect how the brain grows and functions during these critical early years.
Research suggests that babies who have experienced invasive Group B Streptococcus (iGBS) infections may be at a higher risk for neurodevelopmental challenges, yet there is still much to learn about how iGBS exposure impacts children as they grow.
The COMPPASS Registry is working to bridge this gap by using validated surveys to track developmental milestones and identify early signs of potential difficulties. Because young brains are highly adaptable (neuroplasticity), identifying and addressing concerns early can help children develop the skills they need to thrive.
​
​
Knowledge Empowers
Understanding the short and long-term risks associated with iGBS disease is not just important for parents—it’s essential for ensuring that children receive the right support at the right time.
With more research, families will have better access to early screenings, therapies, and educational resources, helping them make informed decisions about their child’s development.
The COMPASS Registry aims to also support doctors, researchers, and policymakers in creating stronger healthcare guidelines and interventions that improve outcomes for children affected by iGBS.
By participating in the COMPPASS Registry, families contribute to a future where every child has the opportunity to reach their full potential.
